Your browser doesn't support javascript.
loading
Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies.
Pincez, Thomas; Bruneau, Julie; Berteloot, Laureline; Piekarski, Eve; Thomas, Caroline; Marçais, Ambroise; Trinquand, Amélie; Castelle, Martin; Garcelon, Nicolas; Plantaz, Dominique; Cheminant, Morgane; Moshous, Despina; Molina, Thierry Jo; Hermine, Olivier; Macintyre, Elizabeth; Fischer, Alain; Blanche, Stéphane; Suarez, Felipe; Neven, Bénédicte.
Afiliação
  • Pincez T; Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris.
  • Bruneau J; Pathology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris.
  • Berteloot L; Medical Imaging Department, Hôpital Necker-Enfants Malades, APHP, Paris.
  • Piekarski E; Nuclear Medicine Department, Hôpital Bichat-Claude Bernard, AP-HP, Paris.
  • Thomas C; Pediatric Oncology-Hematology Department, Hôpital Enfant-Adolescent, CHU Nantes, Nantes.
  • Marçais A; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris; Department of Hematology, Hôpital Necker-Enfants Malades, AP-HP, Paris.
  • Trinquand A; Laboratory of Onco-Hematology, Hôpital Necker-Enfants Malades, AP-HP, Paris.
  • Castelle M; Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris.
  • Garcelon N; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris.
  • Plantaz D; Pediatric Hematology-Oncology Department, Grenoble University Hospital, Grenoble.
  • Cheminant M; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris; Department of Hematology, Hôpital Necker-Enfants Malades, AP-HP, Paris.
  • Moshous D; Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris.
  • Molina TJ; Pathology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris.
  • Hermine O; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris; Department of Hematology, Hôpital Necker-Enfants Malades, AP-HP, Paris.
  • Macintyre E; Paris University, Paris; Laboratory of Onco-Hematology, Hôpital Necker-Enfants Malades, AP-HP, Paris; INSERM UMR 1151, Institut Necker-Enfants Malades, Paris.
  • Fischer A; Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris; Collège de France, Paris, France.
  • Blanche S; Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris.
  • Suarez F; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris; Department of Hematology, Hôpital Necker-Enfants Malades, AP-HP, Paris.
  • Neven B; Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris. benedicte.neven@aphp.fr.
Haematologica ; 105(9): e461-464, 2020 09 01.
Article em En | MEDLINE | ID: mdl-33054064
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoconjugados / Transtornos Linfoproliferativos Limite: Humans Idioma: En Ano de publicação: 2020
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoconjugados / Transtornos Linfoproliferativos Limite: Humans Idioma: En Ano de publicação: 2020